5 research outputs found
Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents
Novel
rhodium, iridium, and ruthenium half-sandwich complexes containing
(<i>N</i>,<i>N</i>)-bound picolinamide ligands
have been prepared for use as anticancer agents. The complexes show
promising cytotoxicities, with the presence, position, and number
of halides having a significant effect on the corresponding IC<sub>50</sub> values. One ruthenium complex was found to be more cytotoxic
than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively,
and it remains active with MCF-7 cells even under hypoxic conditions,
making it a promising candidate for <i>in vivo</i> studies
Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents
Novel
rhodium, iridium, and ruthenium half-sandwich complexes containing
(<i>N</i>,<i>N</i>)-bound picolinamide ligands
have been prepared for use as anticancer agents. The complexes show
promising cytotoxicities, with the presence, position, and number
of halides having a significant effect on the corresponding IC<sub>50</sub> values. One ruthenium complex was found to be more cytotoxic
than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively,
and it remains active with MCF-7 cells even under hypoxic conditions,
making it a promising candidate for <i>in vivo</i> studies
Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents
Novel
rhodium, iridium, and ruthenium half-sandwich complexes containing
(<i>N</i>,<i>N</i>)-bound picolinamide ligands
have been prepared for use as anticancer agents. The complexes show
promising cytotoxicities, with the presence, position, and number
of halides having a significant effect on the corresponding IC<sub>50</sub> values. One ruthenium complex was found to be more cytotoxic
than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively,
and it remains active with MCF-7 cells even under hypoxic conditions,
making it a promising candidate for <i>in vivo</i> studies
Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents
Novel
rhodium, iridium, and ruthenium half-sandwich complexes containing
(<i>N</i>,<i>N</i>)-bound picolinamide ligands
have been prepared for use as anticancer agents. The complexes show
promising cytotoxicities, with the presence, position, and number
of halides having a significant effect on the corresponding IC<sub>50</sub> values. One ruthenium complex was found to be more cytotoxic
than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively,
and it remains active with MCF-7 cells even under hypoxic conditions,
making it a promising candidate for <i>in vivo</i> studies
Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents
Novel
rhodium, iridium, and ruthenium half-sandwich complexes containing
(<i>N</i>,<i>N</i>)-bound picolinamide ligands
have been prepared for use as anticancer agents. The complexes show
promising cytotoxicities, with the presence, position, and number
of halides having a significant effect on the corresponding IC<sub>50</sub> values. One ruthenium complex was found to be more cytotoxic
than cisplatin on HT-29 and MCF-7 cells after 5 days and 1 h, respectively,
and it remains active with MCF-7 cells even under hypoxic conditions,
making it a promising candidate for <i>in vivo</i> studies